Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB023 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| BIIB023 | EXPERIMENTAL | Participants receive intravenous (IV) infusions of BIIB023 |
| Placebo | PLACEBO_COMPARATOR | Participants receive intravenous (IV) infusions of placebo |
| 1 | EXPERIMENTAL | BIIB023 |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BIIB023 | BIOLOGICAL | Intravenous (IV) infusions |
| Placebo | BIOLOGICAL | Matched placebo |
| Placebo (sterile normal saline) | OTHER | Single IV dose of Placebo |
Key Inclusion Criteria: * Deemed healthy as determined by the Investigator based on medical history, 12-lead electrocardiogram, vital signs, and clinical laboratory parameters at Screening, and physical examination at Baseline * Body mass index (BMI) between 18.5 and 32 kg/m2, inclusive, at the tim...
BIIB023 is an investigational monoclonal antibody being studied for use in rheumatoid arthritis and in healthy volunteers. It has been evaluated in Phase 1 clinical trials for these conditions, though it is not approved and remains in clinical development.
BIIB023 is an anti-TWEAK monoclonal antibody, meaning it targets the cytokine TWEAK. It was studied in a Phase 1 trial in subjects with rheumatoid arthritis to assess its effects, though no efficacy data from that trial is available here.
BIIB023 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker BIIB. Biogen has sponsored the clinical trials of BIIB023 in rheumatoid arthritis and healthy volunteer studies.
BIIB023 is in Phase 1 clinical development. All three completed trials of BIIB023 were Phase 1 studies, including trials in rheumatoid arthritis and healthy volunteers. It is investigational and has not been approved by regulatory authorities.
BIIB023 has been studied in three completed Phase 1 trials: NCT00771329 in rheumatoid arthritis, NCT01407406 in healthy volunteers of different ethnicities, and NCT01943513 in healthy male volunteers for muscle atrophy. All trials are completed.
BIIB023 is an anti-TWEAK monoclonal antibody, and the trial NCT00771329 is titled 'BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis.' This indicates BIIB023 is the drug being evaluated as an anti-TWEAK agent in that study.